Literature DB >> 10644363

Modulation of major histocompatibility class II protein expression by varicella-zoster virus.

A Abendroth1, B Slobedman, E Lee, E Mellins, M Wallace, A M Arvin.   

Abstract

We sought to investigate the effects of varicella-zoster virus (VZV) infection on gamma interferon (IFN-gamma)-stimulated expression of cell surface major histocompatibility complex (MHC) class II molecules on human fibroblasts. IFN-gamma treatment induced cell surface MHC class II expression on 60 to 86% of uninfected cells, compared to 20 to 30% of cells which had been infected with VZV prior to the addition of IFN-gamma. In contrast, cells that were treated with IFN-gamma before VZV infection had profiles of MHC class II expression similar to those of uninfected cell populations. Neither IFN-gamma treatment nor VZV infection affected the expression of transferrin receptor (CD71). In situ and Northern blot hybridization of MHC II (MHC class II DR-alpha) RNA expression in response to IFN-gamma stimulation revealed that MHC class II DR-alpha mRNA accumulated in uninfected cells but not in cells infected with VZV. When skin biopsies of varicella lesions were analyzed by in situ hybridization, MHC class II transcripts were detected in areas around lesions but not in cells that were infected with VZV. VZV infection inhibited the expression of Stat 1alpha and Jak2 proteins but had little effect on Jak1. Analysis of regulatory events in the IFN-gamma signaling pathway showed that VZV infection inhibited transcription of interferon regulatory factor 1 and the MHC class II transactivator. This is the first report that VZV encodes an immunomodulatory function which directly interferes with the IFN-gamma signal transduction via the Jak/Stat pathway and enables the virus to inhibit IFN-gamma induction of cell surface MHC class II expression. This inhibition of MHC class II expression on VZV-infected cells in vivo may transiently protect cells from CD4(+) T-cell immune surveillance, facilitating local virus replication and transmission during the first few days of cutaneous lesion formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644363      PMCID: PMC111668          DOI: 10.1128/jvi.74.4.1900-1907.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Sequences and factors: a guide to MHC class-II transcription.

Authors:  L H Glimcher; C J Kara
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

2.  Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus.

Authors:  R E Bergen; M Sharp; A Sanchez; A K Judd; A M Arvin
Journal:  Viral Immunol       Date:  1991       Impact factor: 2.257

3.  The role of interferon beta in human cytomegalovirus-mediated inhibition of HLA DR induction on endothelial cells.

Authors:  D D Sedmak; S Chaiwiriyakul; D A Knight; W J Waldmann
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Tumor necrosis factor, interleukin-2, and interferon-gamma in adult varicella.

Authors:  M R Wallace; I Woelfl; W A Bowler; P E Olson; N B Murray; S K Brodine; E C Oldfield; A M Arvin
Journal:  J Med Virol       Date:  1994-05       Impact factor: 2.327

5.  Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma.

Authors:  Z Mikloska; A M Kesson; M E Penfold; A L Cunningham
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

6.  Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.

Authors:  M A Meraz; J M White; K C Sheehan; E A Bach; S J Rodig; A S Dighe; D H Kaplan; J K Riley; A C Greenlund; D Campbell; K Carver-Moore; R N DuBois; R Clark; M Aguet; R D Schreiber
Journal:  Cell       Date:  1996-02-09       Impact factor: 41.582

7.  Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine.

Authors:  M Sharp; K Terada; A Wilson; S Nader; P E Kinchington; W T Ruyechan; J Hay; A M Arvin
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

8.  Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway.

Authors:  D M Miller; B M Rahill; J M Boss; M D Lairmore; J E Durbin; J W Waldman; D D Sedmak
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

9.  Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes.

Authors:  C H Chang; J D Fontes; M Peterlin; R A Flavell
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

10.  Class II transactivator regulates the expression of multiple genes involved in antigen presentation.

Authors:  C H Chang; R A Flavell
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  42 in total

1.  Varicella-zoster virus productively infects mature dendritic cells and alters their immune function.

Authors:  Gavin Morrow; Barry Slobedman; Anthony L Cunningham; Allison Abendroth
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Mycobacterium avium subsp. paratuberculosis inhibits gamma interferon-induced signaling in bovine monocytes: insights into the cellular mechanisms of Johne's disease.

Authors:  Ryan J Arsenault; Yue Li; Kelli Bell; Kimberley Doig; Andrew Potter; Philip J Griebel; Anthony Kusalik; Scott Napper
Journal:  Infect Immun       Date:  2012-06-11       Impact factor: 3.441

3.  Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction.

Authors:  Cindy Gutzeit; Martin J Raftery; Matthias Peiser; Karsten B Tischer; Martina Ulrich; Melanie Eberhardt; Eggert Stockfleth; Thomas Giese; Andreas Sauerbrei; Craig T Morita; Günther Schönrich
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

Review 4.  Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model.

Authors:  Chia-Chi Ku; Jaya Besser; Allison Abendroth; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 5.  Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.

Authors:  Emmanuel J Wiertz; Robert Devlin; Helen L Collins; Maaike E Ressing
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.

Authors:  L M Butler; H C Jeffery; R L Wheat; H M Long; P C Rae; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

7.  Infection and Functional Modulation of Human Monocytes and Macrophages by Varicella-Zoster Virus.

Authors:  Megan Steain; Barry Slobedman; Allison Abendroth; Jarrod J Kennedy
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

8.  T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection.

Authors:  Anne Schaap; Jean-Francois Fortin; Marvin Sommer; Leigh Zerboni; Shaye Stamatis; Chia-Chi Ku; Garry P Nolan; Ann M Arvin
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

9.  Simian varicella virus inhibits the interferon gamma signalling pathway.

Authors:  Werner J D Ouwendijk; Suzanne van Veen; Ravi Mahalingam; Georges M G M Verjans
Journal:  J Gen Virol       Date:  2017-10       Impact factor: 3.891

10.  Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.

Authors:  Jianmin Zuo; Andrew D Hislop; Carol S Leung; Shereen Sabbah; Martin Rowe
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.